MetLife Investment Management’s SpringWorks Therapeutics SWTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-43,379
| Closed | -$2.04M | – | 2915 |
|
|
2025
Q2 | $2.04M | Buy |
43,379
+2,615
| +6% | +$116K | 0.01% | 979 |
|
|
2025
Q1 | $1.8M | Sell |
40,764
-1,325
| -3% | -$61K | 0.01% | 1090 |
|
|
2024
Q4 | $1.52M | Buy |
42,089
+2,702
| +7% | +$94.4K | 0.01% | 1203 |
|
|
2024
Q3 | $1.26M | Hold |
39,387
| – | – | 0.01% | 1260 |
|
|
2024
Q2 | $1.48M | Buy |
39,387
+4,467
| +13% | +$188K | 0.01% | 1133 |
|
|
2024
Q1 | $1.72M | Sell |
34,920
-452
| -1% | -$20.9K | 0.01% | 1027 |
|
|
2023
Q4 | $1.29M | Buy |
35,372
+4,636
| +15% | +$121K | 0.01% | 1170 |
|
|
2023
Q3 | $711K | Hold |
30,736
| – | – | 0.01% | 1420 |
|
|
2023
Q2 | $806K | Buy |
30,736
+11,939
| +64% | +$314K | 0.01% | 1389 |
|
|
2023
Q1 | $484K | Buy |
18,797
+375
| +2% | +$11K | ﹤0.01% | 1664 |
|
|
2022
Q4 | $479K | Hold |
18,422
| – | – | ﹤0.01% | 1672 |
|
|
2022
Q3 | $526K | Buy |
18,422
+1,454
| +9% | +$41.7K | ﹤0.01% | 1598 |
|
|
2022
Q2 | $418K | Buy |
16,968
+887
| +6% | +$32.4K | ﹤0.01% | 1795 |
|
|
2022
Q1 | $908K | Buy |
16,081
+5,529
| +52% | +$316K | 0.01% | 1394 |
|
|
2021
Q4 | $654K | Hold |
10,552
| – | – | 0.01% | 1355 |
|
|
2021
Q3 | $669K | Hold |
10,552
| – | – | 0.01% | 1359 |
|
|
2021
Q2 | $870K | Buy |
10,552
+912
| +9% | +$69.2K | 0.01% | 1244 |
|
|
2021
Q1 | $709K | Hold |
9,640
| – | – | 0.01% | 1324 |
|
|
2020
Q4 | $699K | Hold |
9,640
| – | – | 0.01% | 1300 |
|
|
2020
Q3 | $460K | Hold |
9,640
| – | – | 0.01% | 1408 |
|
|
2020
Q2 | $405K | Buy |
9,640
+4,653
| +93% | +$166K | ﹤0.01% | 1495 |
|
|
2020
Q1 | $135K | Sell |
4,987
-3,208
| -39% | -$105K | ﹤0.01% | 1914 |
|
|
2019
Q4 | $315K | Buy |
+8,195
| New | +$192K | ﹤0.01% | 1712 |
|
Other funds holding SWTX
MetLife Investment Management's SWTX Position: Q3 2025 in Review
MetLife Investment Management sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 43,379 shares — an estimated $2.04M sold.
MetLife Investment Management first reported a position in SWTX in Q4 2019 and held it in 23 quarters. The position peaked at $2.04M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.
- MetLife Investment Management reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
- MetLife Investment Management sold 43,379 SpringWorks Therapeutics shares in Q3 2025, an estimated $2.04M.
- MetLife Investment Management first reported a position in SpringWorks Therapeutics in Q4 2019 and held it in 23 quarters.
- MetLife Investment Management's SpringWorks Therapeutics position peaked at $2.04M in Q2 2025.
- 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.
Based on MetLife Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.